AngioDynamics vs AtriCure
ANGO and ATRC side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANGO and ATRC compare
AtriCure is the larger company, worth 5.6 times as much as AngioDynamics ($2.9B against $522M).
AtriCure grew revenue faster over the last twelve months (13.8% versus 8.2% for AngioDynamics).
AtriCure keeps more of each dollar of sales as profit, with a net margin of 2.5% compared with −10.1% at AngioDynamics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANGO | ATRC |
|---|---|---|
| Size and price | ||
| Market cap | $522M | $2.9B |
| Share price | $12.42 | $57.53 |
| Change, 1 year | 1.1% | 79.8% |
| Change, 5 years | −56.5% | −25.9% |
| Beta (5Y) | 0.34 | 1.26 |
| Employees | 632 | 1,350 |
| StockData Score | ||
| Total score | 12 | 12 |
| Valuation score | 2 (better) | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 3 | 3 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 192× |
| P/S | 1.6× (better) | 5.0× |
| P/B | 3.2× (better) | 5.5× |
| EV/EBITDA | – | 164× |
| P/FCF | 362× | 55.3× (better) |
| FCF yield | 0.28% | 1.8% (better) |
| Fair value | $13.23 | $8.19 |
| Margin of safety | 6.1% (better) | −603% |
| Growth | ||
| Revenue growth (TTM) | 8.2% | 13.8% (better) |
| Revenue growth, 5Y average | 1.9% | 20.9% (better) |
| Profitability | ||
| Gross margin | 55.7% | 76.7% (better) |
| Operating margin | −11.2% | 2.9% (better) |
| Net margin | −10.1% | 2.5% (better) |
| FCF margin | 0.44% | 9.0% (better) |
| Return on equity | −19.2% | 2.9% (better) |
| Return on invested capital | −21.4% | 3.9% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.11 (better) |
| Net debt / EBITDA | – | −7.40 |
| Interest coverage | – | 2.9× |
| Current ratio | 2.40 | 4.33 (better) |
| Altman Z-score | 2.54 | 10.11 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 91.0% | 104% |
| Held by insiders | 5.8% | 4.0% |
| Insider net buying, 12 months | −$655K (better) | −$4.4M |
| Short interest, % of float | 5.1% | 10.0% |
Go deeper
- ANGO stock overview
- ANGO income statement
- ANGO valuation and score
- ATRC stock overview
- ATRC income statement
- ATRC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.